LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

Search

Edwards Lifesciences Corp

Închisă

SectorSănătate

87.56 1.84

Rezumat

Modificarea prețului

24h

Curent

Minim

85.16

Maxim

87.91

Indicatori cheie

By Trading Economics

Venit

290M

381M

Vânzări

79M

1.6B

P/E

Medie Sector

46.368

49.701

EPS

0.78

Marjă de profit

23.092

Angajați

16,000

EBITDA

382M

515M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+14.08% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 iul. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

2.1B

49B

Deschiderea anterioară

85.72

Închiderea anterioară

87.56

Sentimentul știrilor

By Acuity

81%

19%

311 / 344 Clasament în Healthcare

Edwards Lifesciences Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 ian. 2026, 00:16 UTC

Achiziții, Fuziuni, Preluări

Edwards Lifesciences Drops Merger With JenaValve

6 aug. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

Comparație

Modificare preț

Edwards Lifesciences Corp Așteptări

Obiectiv de preț

By TipRanks

14.08% sus

Prognoză pe 12 luni

Medie 97.86 USD  14.08%

Maxim 110 USD

Minim 85 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEdwards Lifesciences Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

18 ratings

15

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

311 / 344 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat